120 related articles for article (PubMed ID: 37712353)
1. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
Adv Sci (Weinh); 2023 Sep; 10(26):e2305364. PubMed ID: 37712353
[No Abstract] [Full Text] [Related]
2. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
Adv Sci (Weinh); 2023 May; 10(13):e2300288. PubMed ID: 36866919
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins.
Wu Y; Lin B; Lu Y; Li L; Deng K; Zhang S; Zhang H; Yang C; Zhu Z
Angew Chem Int Ed Engl; 2023 Apr; 62(15):e202218106. PubMed ID: 36722696
[TBL] [Abstract][Full Text] [Related]
4. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y
Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817
[TBL] [Abstract][Full Text] [Related]
5. LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins.
Ramadas B; Kumar Pain P; Manna D
ChemMedChem; 2021 Oct; 16(19):2951-2953. PubMed ID: 34296796
[TBL] [Abstract][Full Text] [Related]
6. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation.
Ahn G; Banik SM; Miller CL; Riley NM; Cochran JR; Bertozzi CR
Nat Chem Biol; 2021 Sep; 17(9):937-946. PubMed ID: 33767387
[TBL] [Abstract][Full Text] [Related]
7. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma.
Zhang P; Lu X; Tao K; Shi L; Li W; Wang G; Wu K
J Surg Res; 2015 Mar; 194(1):107-13. PubMed ID: 25450598
[TBL] [Abstract][Full Text] [Related]
8. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.
Sammar M; Siwetz M; Meiri H; Fleming V; Altevogt P; Huppertz B
Histochem Cell Biol; 2017 May; 147(5):565-574. PubMed ID: 28012129
[TBL] [Abstract][Full Text] [Related]
10. CD24-Siglec interactions in inflammatory diseases.
Liu Y; Zheng P
Front Immunol; 2023; 14():1174789. PubMed ID: 37228622
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
12. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
Yin SS; Gao FH
Front Immunol; 2020; 11():1324. PubMed ID: 32765491
[TBL] [Abstract][Full Text] [Related]
14. Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.
Chen GY; Brown NK; Zheng P; Liu Y
Glycobiology; 2014 Sep; 24(9):800-6. PubMed ID: 24996822
[TBL] [Abstract][Full Text] [Related]
15. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.
Toubai T; Hou G; Mathewson N; Liu C; Wang Y; Oravecz-Wilson K; Cummings E; Rossi C; Evers R; Sun Y; Wu J; Choi SW; Fang D; Zheng P; Liu Y; Reddy P
Blood; 2014 May; 123(22):3512-23. PubMed ID: 24695850
[TBL] [Abstract][Full Text] [Related]
16. The biological roles of CD24 in ovarian cancer: old story, but new tales.
Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
[TBL] [Abstract][Full Text] [Related]
17. CD24: A Novel Target for Cancer Immunotherapy.
Panagiotou E; Syrigos NK; Charpidou A; Kotteas E; Vathiotis IA
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013184
[TBL] [Abstract][Full Text] [Related]
18. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns.
Liu Y; Chen GY; Zheng P
Trends Immunol; 2009 Dec; 30(12):557-61. PubMed ID: 19786366
[TBL] [Abstract][Full Text] [Related]
19. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses.
Orr SJ; Morgan NM; Buick RJ; Boyd CR; Elliott J; Burrows JF; Jefferies CA; Crocker PR; Johnston JA
J Biol Chem; 2007 Feb; 282(6):3418-22. PubMed ID: 17138568
[TBL] [Abstract][Full Text] [Related]
20. N-glycosylation of Siglec-15 decreases its lysosome-dependent degradation and promotes its transportation to the cell membrane.
Chen X; Dang X; Song J; Wang G; Liu C; Cui L; Huang Z
Biochem Biophys Res Commun; 2020 Nov; 533(1):77-82. PubMed ID: 32921411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
